Recurrent Immune Checkpoint Inhibitor Hepatitis With Pembrolizumab Cessation: A Stubborn Case of Delayed-Onset,
Allison Ladetto1, Daniel T Gildea2, Abhishek Shenoy2,3
1School of Medicine, Virginia Commonwealth University, Richmond, VA.
Abstract:
Immune checkpoint inhibitors such as pembrolizumab are increasingly used in cancer therapy, yet immune-related adverse events like immune-mediated liver injury from checkpoint inhibitors remain challenging to diagnose and manage. Most cases arise early in treatment and respond to corticosteroids, but rare delayed or refractory presentations have been described. We report a unique case of delayed-onset, steroid-refractory immune-mediated liver injury from checkpoint inhibitors requiring escalation of therapy despite prolonged discontinuation of the causative agent, highlighting the need for continued vigilance and individualized management strategies in patients receiving immune checkpoint inhibitors.
Related Concept Videos
Hepatitis
Hypersensitivity Reactions: Cytolytic Reactions
Tumor Immunotherapy
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents


